The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An acetate ester resulting from the formal condensation of the 17alpha-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control.
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
Medroxyprogesterone Acetate results in decreased activity of AKR1C4 protein AKR1C4 gene polymorphism affects the susceptibility to [Estrogens co-treated with Medroxyprogesterone Acetate]
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost] Medroxyprogesterone Acetate results in decreased activity of AKR1C3 protein
Medroxyprogesterone Acetate inhibits the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA]]
Medroxyprogesterone Acetate results in decreased expression of CCL2 mRNA; Medroxyprogesterone Acetate results in decreased expression of CCL2 protein Medroxyprogesterone Acetate results in decreased secretion of CCL2 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein
[Bezafibrate co-treated with Medroxyprogesterone Acetate] results in decreased activity of CD40LG protein Medroxyprogesterone Acetate results in decreased activity of CD40LG protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased expression of CDKN1B protein]; Mifepristone inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol] results in increased expression of CDKN1B protein]
Medroxyprogesterone Acetate results in increased expression of CNR1 mRNA [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; Medroxyprogesterone Acetate inhibits the reaction [benzo(a)pyrene 7,8-dihydrodiol results in increased expression of CYP1A1 mRNA] Medroxyprogesterone Acetate results in increased expression of CYP1A1 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; CYP1B1 gene polymorphism affects the susceptibility to [Estrogens co-treated with Medroxyprogesterone Acetate]
Medroxyprogesterone Acetate results in increased expression of CYP3A4 mRNA; Medroxyprogesterone Acetate results in increased expression of CYP3A4 protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
Medroxyprogesterone Acetate results in decreased expression of DIO2 mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA
ESR1 protein promotes the reaction [Medroxyprogesterone Acetate results in increased expression of EPHX1 protein] Medroxyprogesterone Acetate results in increased expression of EPHX1 mRNA; Medroxyprogesterone Acetate results in increased expression of EPHX1 protein
ESR1 protein promotes the reaction [Medroxyprogesterone Acetate results in increased expression of EPHX1 protein] Medroxyprogesterone Acetate results in decreased expression of ESR1 mRNA
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] Medroxyprogesterone Acetate results in decreased expression of EZH2 mRNA; Medroxyprogesterone Acetate results in decreased expression of EZH2 protein
Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA] Medroxyprogesterone Acetate results in increased expression of F2
Medroxyprogesterone Acetate results in increased expression of F2R protein Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of F2R mRNA] Medroxyprogesterone Acetate results in increased expression of F2R mRNA; Medroxyprogesterone Acetate results in increased expression of F2R protein
Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA] Medroxyprogesterone Acetate results in increased expression of F3 protein
Medroxyprogesterone Acetate results in increased expression of FBLN1 mRNA; Medroxyprogesterone Acetate results in increased expression of FBLN1 protein Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of FBLN1 mRNA]
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA; [Medroxyprogesterone Acetate co-treated with Carbon Tetrachloride] results in increased expression of FN1 protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein]
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]
[Medroxyprogesterone Acetate co-treated with Estrogens] results in increased expression of HOXA10 mRNA; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of HOXA10 mRNA]
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IFNG protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased expression of IGFBP1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of IGFBP1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IL1B protein Medroxyprogesterone Acetate results in decreased expression of IL1B mRNA
[Polyphenols co-treated with Antioxidants co-treated with Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Medroxyprogesterone Acetate co-treated with Celecoxib] results in decreased expression of IL6 Medroxyprogesterone Acetate results in decreased expression of IL6 mRNA Medroxyprogesterone Acetate results in decreased secretion of IL6 protein [Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased secretion of IL6 protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased activity of MMP2 protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA Medroxyprogesterone Acetate results in decreased activity of MMP2 protein
[Indomethacin co-treated with Medroxyprogesterone Acetate] results in decreased activity of MMP9 protein Medroxyprogesterone Acetate results in decreased expression of MMP9 mRNA Medroxyprogesterone Acetate results in decreased activity of MMP9 protein
Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased activity of NOS3 protein]; Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of NOS3 protein]
Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of NPY1R mRNA] Medroxyprogesterone Acetate results in decreased expression of NPY1R mRNA
NR3C1 protein affects the susceptibility to Medroxyprogesterone Acetate [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 protein
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein
Medroxyprogesterone Acetate results in decreased expression of NT5E mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA
Medroxyprogesterone Acetate results in decreased expression of PGR protein Medroxyprogesterone Acetate results in decreased expression of PGR mRNA; Medroxyprogesterone Acetate results in decreased expression of PGR protein Medroxyprogesterone Acetate promotes the reaction [PGR protein binds to NCOA1 protein]
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Dinoprostone promotes the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of PRL mRNA]; Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]
Medroxyprogesterone Acetate results in increased expression of SERPINE1 mRNA; Medroxyprogesterone Acetate results in increased expression of SERPINE1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein
[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of SOD1 mRNA; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased activity of SOD1 protein; [Estradiol deficiency co-treated with Medroxyprogesterone Acetate deficiency] results in decreased expression of SOD1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD1 mRNA; Estradiol promotes the reaction [Medroxyprogesterone Acetate results in increased activity of SOD1 protein] Medroxyprogesterone Acetate results in increased expression of SOD1 mRNA
[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD2 protein; [Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; Medroxyprogesterone Acetate promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased activity of SOD2 protein]; WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] [Medroxyprogesterone Acetate co-treated with Estradiol] affects the expression of SOD2 Medroxyprogesterone Acetate affects the expression of SOD2 Medroxyprogesterone Acetate results in increased activity of SOD2 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA
[Estradiol co-treated with Medroxyprogesterone Acetate] results in decreased secretion of TNF protein; [Polyphenols co-treated with Antioxidants co-treated with Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Medroxyprogesterone Acetate co-treated with Celecoxib] results in decreased expression of TNF
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein
Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]; Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Mifepristone inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]
VDR gene polymorphism affects the susceptibility to [Alendronate co-treated with Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate]; VDR gene polymorphism affects the susceptibility to [Estrogens, Conjugated (USP) co-treated with Medroxyprogesterone Acetate]
Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA; Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA alternative form Mifepristone inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA]
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA; WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] Medroxyprogesterone Acetate results in increased expression of WNT5A mRNA
browse the term
